LT2900657T - Cikliniai eterio pirazol-4-il-heterociklil-karboksamido junginiai ir jų naudojimo būdai - Google Patents

Cikliniai eterio pirazol-4-il-heterociklil-karboksamido junginiai ir jų naudojimo būdai

Info

Publication number
LT2900657T
LT2900657T LTEP13770441.7T LT13770441T LT2900657T LT 2900657 T LT2900657 T LT 2900657T LT 13770441 T LT13770441 T LT 13770441T LT 2900657 T LT2900657 T LT 2900657T
Authority
LT
Lithuania
Prior art keywords
heterocyclyl
methods
cyclic ether
carboxamide compounds
pyrazol
Prior art date
Application number
LTEP13770441.7T
Other languages
English (en)
Inventor
Wesley Blackaby
Jason Burch
Alastair Hodges
Andrew Sharpe
Minghua Sun
Xiaojing Wang
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261521&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2900657(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of LT2900657T publication Critical patent/LT2900657T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
LTEP13770441.7T 2012-09-26 2013-09-25 Cikliniai eterio pirazol-4-il-heterociklil-karboksamido junginiai ir jų naudojimo būdai LT2900657T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705791P 2012-09-26 2012-09-26
US201361864882P 2013-08-12 2013-08-12
PCT/EP2013/069892 WO2014048939A1 (en) 2012-09-26 2013-09-25 Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Publications (1)

Publication Number Publication Date
LT2900657T true LT2900657T (lt) 2020-05-25

Family

ID=49261521

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13770441.7T LT2900657T (lt) 2012-09-26 2013-09-25 Cikliniai eterio pirazol-4-il-heterociklil-karboksamido junginiai ir jų naudojimo būdai

Country Status (28)

Country Link
US (2) US9328106B2 (lt)
EP (1) EP2900657B1 (lt)
JP (2) JP6666147B2 (lt)
KR (1) KR102281288B1 (lt)
CN (1) CN104640858B (lt)
AU (2) AU2013322736A1 (lt)
BR (1) BR112015006019B1 (lt)
CA (1) CA2881068C (lt)
CL (1) CL2015000530A1 (lt)
CR (1) CR20150119A (lt)
DK (1) DK2900657T3 (lt)
EA (1) EA031622B1 (lt)
ES (1) ES2791648T3 (lt)
HK (1) HK1206737A1 (lt)
HR (1) HRP20200681T1 (lt)
HU (1) HUE049611T2 (lt)
IL (1) IL237159A0 (lt)
LT (1) LT2900657T (lt)
MX (1) MX2015003513A (lt)
PE (1) PE20151375A1 (lt)
PH (1) PH12015500488B1 (lt)
PL (1) PL2900657T3 (lt)
PT (1) PT2900657T (lt)
RS (1) RS60202B1 (lt)
SG (1) SG11201502343RA (lt)
SI (1) SI2900657T1 (lt)
UA (1) UA119229C2 (lt)
WO (1) WO2014048939A1 (lt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2794627T (pt) 2011-12-22 2018-12-19 Janssen Biopharma Inc Nucleósidos substituídos, nucleótidos e análogos dos mesmos
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6218808B2 (ja) * 2012-05-03 2017-10-25 ジェネンテック， インコーポレイテッド Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
AR091156A1 (es) 2012-05-25 2015-01-14 Jansen R & D Ireland Nucleosidos de espirooxetano de uracilo
PE20151433A1 (es) 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
SI2945939T1 (sl) 2013-01-15 2020-08-31 Incyte Holdings Corporation Spojine tiazolkarboksamidov in piridinkarboksamida uporabne kot zaviralci PIM kinaze
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
CA2939848A1 (en) * 2014-03-18 2015-09-24 F. Hoffmann-La Roche Ag Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
SG11201707752SA (en) * 2015-04-22 2017-11-29 Rigel Pharmaceuticals Inc Pyrazole compounds and method for making and using the compounds
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
CN105254624B (zh) * 2015-09-18 2019-08-09 上海吉铠医药科技有限公司 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3377488B1 (en) 2015-11-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
KR20180100585A (ko) 2015-12-22 2018-09-11 인사이트 코포레이션 면역조절제로서의 헤테로사이클릭 화합물
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
PE20190731A1 (es) 2016-06-20 2019-05-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
PE20200005A1 (es) 2016-12-22 2020-01-06 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
AU2019272342B2 (en) 2018-03-08 2024-03-07 Incyte Corporation Aminopyrazine diol compounds as PI3K-y inhibitors
AU2019245288C1 (en) 2018-03-30 2024-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2019267824B2 (en) 2018-05-11 2023-10-05 Incyte Corporation Tetrahydro-imidazo(4,5-C)pyridine derivatives as PD-L1 immunomodulators
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
AU2020335903A1 (en) 2019-08-30 2022-03-24 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
TW202116309A (zh) * 2019-09-11 2021-05-01 瑞士商赫孚孟拉羅股份公司 藥劑之製備方法
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
JP2023500395A (ja) 2019-11-11 2023-01-05 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩及び結晶形態
BR112022011838A2 (pt) 2019-12-20 2022-08-30 Pfizer Derivados de benzimidazol
EP3967307A1 (en) * 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
CN112852960A (zh) * 2020-12-09 2021-05-28 浙江省肿瘤医院 一种甲状腺***状癌生物标记物及其应用
CN112625030A (zh) * 2020-12-25 2021-04-09 杭州澳赛诺生物科技有限公司 一种一锅法合成n-保护3-溴代吡唑的合成方法
WO2023202563A1 (en) * 2022-04-18 2023-10-26 Newbay Technology Development Co., Ltd. Akt inhibitor in combination with pim kinase inhibitor
WO2024082724A1 (en) * 2022-10-17 2024-04-25 Ningbo Newbay Technology Development Co., Ltd. Pim kinase inhibitor in combination with kras inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5831108A (en) 1995-08-03 1998-11-03 California Institute Of Technology High metathesis activity ruthenium and osmium metal carbene complexes
JPH1153696A (ja) 1997-07-31 1999-02-26 Toyota Motor Corp カーブ路警報装置
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US8828902B2 (en) 2001-07-12 2014-09-09 Reaxa Limited Microencapsulated catalyst methods of preparation and method of use thereof
CA2927656C (en) 2005-10-07 2019-09-24 Exelixis, Inc. Mek inhibitors and methods of their use
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
PE20080928A1 (es) * 2006-10-31 2008-08-15 Schering Corp Derivados de anilinopiperazina como inhibidores de proteina quinasa
CA2679659C (en) * 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
CA2708369C (en) 2007-12-12 2017-04-04 Massachusetts Institute Of Technology Ligands for transition-metal-catalyzed cross-couplings, and methods of use thereof
PE20091577A1 (es) 2008-03-03 2009-11-05 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
US8697866B2 (en) * 2008-06-19 2014-04-15 Xcovery Holding Company Llc Substituted pyridazine carboxamide compounds as kinase inhibitor compounds
US8329732B2 (en) 2008-09-02 2012-12-11 Novartis Ag Kinase inhibitors and methods of their use
EP2483277B1 (en) 2009-09-28 2015-12-02 F. Hoffmann-La Roche AG Benzoxepin pi3k inhibitor compounds and methods of use
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
BR112012025480A2 (pt) * 2010-04-07 2020-08-18 F. Hoffmann - La Roche Ag composto, composição farmacêutica composta de um composto, uso do composto e método de tratamento de uma doença ou distúrbio
WO2012004217A1 (en) * 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN103987707B (zh) 2011-09-27 2017-11-07 霍夫曼-拉罗奇有限公司 吡唑‑4‑基‑杂环基‑甲酰胺化合物以及使用方法

Also Published As

Publication number Publication date
SG11201502343RA (en) 2015-04-29
CR20150119A (es) 2015-04-30
BR112015006019A2 (pt) 2017-07-04
JP2015529235A (ja) 2015-10-05
RS60202B1 (sr) 2020-06-30
ES2791648T3 (es) 2020-11-05
AU2013322736A1 (en) 2015-02-26
CL2015000530A1 (es) 2015-07-10
US20140088117A1 (en) 2014-03-27
HRP20200681T1 (hr) 2020-07-24
EP2900657B1 (en) 2020-03-11
PH12015500488A1 (en) 2015-04-20
HK1206737A1 (en) 2016-01-15
EA201590624A1 (ru) 2015-07-30
JP2018162263A (ja) 2018-10-18
PT2900657T (pt) 2020-05-07
PH12015500488B1 (en) 2015-04-20
JP6666147B2 (ja) 2020-03-13
EP2900657A1 (en) 2015-08-05
MX2015003513A (es) 2015-07-17
PL2900657T3 (pl) 2020-07-27
UA119229C2 (uk) 2019-05-27
CN104640858A (zh) 2015-05-20
SI2900657T1 (sl) 2020-07-31
WO2014048939A1 (en) 2014-04-03
EA031622B1 (ru) 2019-01-31
PE20151375A1 (es) 2015-09-18
US20160213652A1 (en) 2016-07-28
CN104640858B (zh) 2018-11-06
US9328106B2 (en) 2016-05-03
IL237159A0 (en) 2015-04-30
KR102281288B1 (ko) 2021-07-26
DK2900657T3 (da) 2020-05-04
AU2018200648B2 (en) 2019-10-31
HUE049611T2 (hu) 2020-09-28
CA2881068A1 (en) 2014-04-03
US9931323B2 (en) 2018-04-03
AU2018200648A1 (en) 2018-02-15
BR112015006019B1 (pt) 2021-01-05
CA2881068C (en) 2021-06-08
KR20150058257A (ko) 2015-05-28

Similar Documents

Publication Publication Date Title
IL237159A0 (en) Pyrazol-4-yl-heterocyclyl-carboxamide cyclic ether compounds and methods of use
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
ZA201405248B (en) Anesthetic compounds and related methods of use
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
ZA201406082B (en) Use of ccr3-inhibitors
EP2812324A4 (en) HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
SG11201403215TA (en) Cyclic compounds and methods of making and using the same
HK1203494A1 (en) Heteroaryl compounds and methods of use thereof
HK1206024A1 (en) Tricyclic compounds and methods of use therefor
EP2906576A4 (en) GLYCOSPHINGOLIPIDES AND METHOD OF USE THEREOF
EP2847193A4 (en) HEZEROARYL COMPOUNDS AND METHOD FOR USE THEREOF
IL239245A0 (en) A new use of Eclidenium
ZA201408128B (en) Etract of greyia radlkoferi and use thereof
EP2841164A4 (en) COMPOSITIONS AND USE PROCEDURES FOR THE SKIN